STOCK TITAN
  1. Home
  2. News
  3. LH

Laboratory Corp. Of America Holdings - LH STOCK NEWS

Welcome to our dedicated news page for Laboratory Of America Holdings (Ticker: LH), a resource for investors and traders seeking the latest updates and insights on Laboratory Of America Holdings.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Laboratory Of America Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Laboratory Of America Holdings's position in the market.

News
The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab
Rhea-AI Summary
The Prelude Network expands its partnership with Labcorp to enhance genetic carrier screening services for patients, including genetic counseling and improved test result turnaround time. Labcorp's contract with insurance companies aims to improve financial access to genetic screening for the U.S. patient population, benefiting patients seeking fertility diagnostics and treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business
Rhea-AI Summary
Labcorp (LH) to acquire select assets of BioReference Health from OPKO Health (OPK) to enhance laboratory services network and expand access to clinical laboratory services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
acquisition
-
News
Labcorp to Announce First Quarter Financial Results on April 25, 2024
Rhea-AI Summary
Labcorp (LH) will release its financial results for Q1 2024 on April 25, 2024. A conference call and webcast will follow to discuss the results. The earnings press release will be available on Labcorp's Investor Relations website. Participants can register to receive dial-in numbers for the call. A replay will be accessible until April 11, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.43%
Tags
earnings
News
Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials
Rhea-AI Summary
Labcorp (NYSE: LH) launches pTau217 test to aid in Alzheimer's disease diagnosis and monitoring, expanding its testing options. The company aims to improve patient care by providing innovative laboratory services in the field of Alzheimer's disease. The test complements Labcorp's existing biomarker testing portfolio, offering physicians and biopharmaceutical partners a valuable tool for clinical trials and research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
clinical trial
-
News
Labcorp Presents New Research Demonstrating Clinical Impact of Precision Diagnostics in Guiding Biomarker-targeted Therapies for Patients with Epithelial Ovarian Cancer
Rhea-AI Summary
Labcorp presents study results at SGO Annual Meeting on Women's Cancer emphasizing the value of biomarker testing in guiding targeted therapies for ovarian cancer patients. The studies highlight the importance of comprehensive genomic profiling in improving patient outcomes and access to effective treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Labcorp Launches Weight Loss Management Testing Solutions
Rhea-AI Summary
Labcorp (LH) introduces Weight Loss Management portfolio to support individuals and physicians with convenient testing options. The offering includes educational resources and proven tests to guide weight loss decisions. GLP-1 medications and bariatric surgery are emphasized for effective weight management. The initiative targets the growing obesity epidemic in the U.S. and aims to provide essential health indicators for personalized treatments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
none
News
PINNACLE FERTILITY PARTNERS WITH LABCORP TO ENHANCE GENETIC TESTING SERVICES
Rhea-AI Summary
Pinnacle Fertility partners with Labcorp to enhance genetic testing services for patients. Labcorp brings over 50 years of experience in women's health and reproductive genetics, aiming to improve patient care and understanding of genetic factors affecting fertility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
partnership
-
News
Labcorp Announces 2023 Fourth Quarter and Full Year Results
Rhea-AI Summary
Labcorp (LH) provides 2024 guidance, reporting Q4 revenue of $3.03 billion, a 3.5% increase, and full-year revenue of $12.16 billion, a 2.5% increase. Adjusted EPS for Q4 was $3.30, full year $13.56, with a projected 2024 range of $14.30 to $15.40. Free cash flow for Q4 was $414.2 million, full year $748.7 million. Labcorp announced six new laboratory partnerships and innovative tests. The company closed a deal with Legacy Health and introduced a Fertility and Family Building Benefit. Labcorp's operating loss in Q4 was ($122.8) million, net losses were $(166.8) million, and diluted EPS was $(1.95). For the full year, net earnings were $380.4 million, diluted EPS $4.33. Operating income decreased to $725.6 million, adjusted EPS was $13.56, and free cash flow was $748.7 million. Revenue growth was driven by acquisitions, organic revenue, and foreign currency translation. Labcorp's 2024 guidance includes revenue growth of 4.7% to 6.5%, adjusted EPS of $14.30 to $15.40, and free cash flow of $1.00 billion to $1.15 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.62%
Tags
none
-
News
Labcorp Named One of the World's Most Admired Companies™ by FORTUNE® Magazine
Rhea-AI Summary
Labcorp (NYSE: LH) has been named to FORTUNE® magazine's list of the World's Most Admired Companies™, recognizing the company's global leadership in innovative laboratory services. Labcorp was one of only five companies in the 'Health Care: Pharmacy and Other Services' industry to achieve Most Admired status, scoring high marks in long-term investment, global competitiveness, and social responsibility. The annual survey is conducted by FORTUNE and Korn Ferry, with top executives, directors, and financial analysts identifying companies with the strongest reputations across nine criteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
News
Labcorp Launches New Test for Risk Assessment and Prognosis of Severe Preeclampsia in Pregnant Women
Rhea-AI Summary
Labcorp (LH) launches FDA-cleared sFlt-1/PlGF KRYPTOR test system to aid in risk assessment of severe preeclampsia, a leading cause of maternal and fetal mortality in the U.S. The test measures two angiogenic biomarkers and helps identify patients at risk of progressing to severe features of preeclampsia within two weeks of the test, leading to enhanced surveillance and accelerated care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
Stock LH logo
Laboratory Corp. Of America Holdings

NYSE:LH

LH Rankings

#584 Ranked by Market Cap
#1736 Ranked by Stock Gains
#1636 Ranked by Dividends

LH Stock Data

17.31B
83.67M
0.34%
98.27%
2.29%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
US
Burlington

About LH

recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.